Stryker Corporation (SYK)

NYSE: SYK · IEX Real-Time Price · USD
240.77
+6.88 (2.94%)
At close: Dec 1, 2022 4:03 PM
239.44
-1.33 (-0.55%)
After-hours: Dec 1, 2022 7:57 PM EST
2.94%
Market Cap 88.51B
Revenue (ttm) 17.95B
Net Income (ttm) 2.46B
Shares Out 378.40M
EPS (ttm) 6.43
PE Ratio 37.44
Forward PE 22.83
Dividend $2.78 (1.15%)
Ex-Dividend Date Sep 29, 2022
Volume 1,662,687
Open 235.66
Previous Close 233.89
Day's Range 235.66 - 242.48
52-Week Range 188.84 - 280.43
Beta 0.99
Analysts Buy
Price Target 243.25 (+1.0%)
Earnings Date Oct 31, 2022

About SYK

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgi... [Read more]

Industry Health Care Equipment & Supplies
Founded 1941
CEO Kevin Lobo
Employees 46,000
Stock Exchange NYSE
Ticker Symbol SYK
Full Company Profile

Financial Performance

In 2021, Stryker's revenue was $17.11 billion, an increase of 19.21% compared to the previous year's $14.35 billion. Earnings were $1.99 billion, an increase of 24.70%.

Financial Statements

Analyst Forecast

According to 34 analysts, the average rating for SYK stock is "Buy." The 12-month stock price forecast is 243.25, which is an increase of 1.03% from the latest price.

Price Target
$243.25
(1.03% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Here's Why You Should Retain Stryker (SYK) Stock For Now

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.

6 days ago - Zacks Investment Research

Stryker opens the OR of the Future for customers to experience tomorrow's OR today

This operating room model puts increased focus on design for patient and staff safety, productivity and operational efficiency—further enabling improvements in quality of care FLOWER MOUND, Texas , Nov....

2 weeks ago - PRNewsWire

Final Trades: Uber, IBM, Stryker & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: IBMUBERPXD
3 weeks ago - CNBC Television

2 Under-the-Radar Medtech Stocks to Buy Now

Don't count out these discounted medical technology stocks.

Other symbols: MASI
3 weeks ago - The Motley Fool

Stryker to participate in the 5th Annual Evercore ISI HealthCONx Conference

Kalamazoo, Michigan, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022.

4 weeks ago - GlobeNewsWire

Stryker's (SYK) Q3 Earnings Miss Estimates, Volume Improves

Stryker's (SYK) third-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurt sales growth.

1 month ago - Zacks Investment Research

Stocks moving on earnings: Stryker, Pitney Bowes, Hologic

Yahoo Finance's Julie Hyman breaks down some trending tickers on the move following earnings.

Other symbols: HOLXPBI
1 month ago - Yahoo Finance

Stryker (SYK) Misses Q3 Earnings Estimates

Stryker (SYK) delivered earnings and revenue surprises of -5.36% and 0.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Stryker Corp. stock falls after company lowers outlook for 2022

Shares of Stryker Corp. SYK, +0.00% fell more than 4% in the extended session Monday after the maker of surgical equipment and other medical devices reported third-quarter results above analyst expectat...

1 month ago - Market Watch

Stryker reports third quarter 2022 operating results

Kalamazoo, Michigan, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2022:

1 month ago - GlobeNewsWire

3 Medical Stocks On the Rebound

As surgeries bounce back toward pre-pandemic levels, these three companies should benefit.

Other symbols: ISRGJNJ
1 month ago - The Motley Fool

Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Income Plus Low Volatility Makes This Fund A Safe Haven

Are you looking for a relatively safe mutual fund haven amid current market carnage? Check out Madison Covered Call & Equity Income Fund (MENYX).

Other symbols: ADMBNTXEOGMDTPFE
1 month ago - Investors Business Daily

Stryker Launches Monterey AL Interbody System with New Pre-clinical Data

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker launched its Monterey AL Interbody System, a stand-alone interbody fusion device designed for anterior lumbar interbody fusion.

1 month ago - Business Wire

Stryker to host conference call on October 31, 2022

Kalamazoo, Michigan, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host a conference call on Monday, October 31, 2022 at 4:30 p.m., Eastern Time, to discuss the Company's ...

2 months ago - GlobeNewsWire

Stryker (SYK) Launches Q Guidance System for Spine Applications

Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during guided spine surgery following its launch.

2 months ago - Zacks Investment Research

Stryker Launches Q Guidance System with Spine Guidance Software

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker announced the launch of its Q Guidance System for spine applications.

2 months ago - Business Wire

Stryker's (SYK) OptaBlate Tumor Ablation System Gets FDA Nod

Stryker's (SYK) OptaBlate bone tumor ablation system is set to offer a reliable solution for people living with painful metastatic tumors.

2 months ago - Zacks Investment Research

3 Undervalued Dividend Champions With High Return Potential

Income investors sometimes take the route of finding the best income stocks to meet their needs based upon criteria like dividend safety, dividend growth potential or historical dividend streak. These c...

Other symbols: DOVPII
2 months ago - InvestorPlace

Diamon Hill CEO names a ‘mispriced' medical technology stock

Stryker Corporation (NYSE: SYK) is a “mispriced” stock that has potential to offer lucrative returns over the long term, says Heather Brilliant. She's the Chief Executive of Diamon Hill Capital Management.

2 months ago - Invezz

There's always an opportunity to find mispriced stocks, says Diamond Hill CEO Heather Brilliant

Heather Brilliant, Diamond Hill Capital Management president and CEO, joins CNBC's 'Squawk Box' ahead of the open on Tuesday to break down potential investment opportunities.

Other symbols: STKL
2 months ago - CNBC Television

Stryker receives FDA clearance for OptaBlate™ Bone Tumor Ablation System

Stryker's first bone tumor ablation system with patented microinfusion technology offers a reliable solution for people living with painful metastatic tumors PORTAGE, Mich., USA, Sept.

2 months ago - PRNewsWire

Should You Buy Stryker Stock Around $225?

Stryker stock (NYSE: SYK), a medical devices company, has seen a 15% fall this year, in line with the broader S&P500 index, down 17%.

2 months ago - Forbes

Stryker Launches Pulse Intelligent Delivery Platform at the 2022 American Orthopaedic Foot & Ankle Society Annual Mee...

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker launched its Pulse Intelligent Delivery Platform, which will debut at the 2022 American Orthopaedic Foot & Ankle Society Annual Meeting.

2 months ago - Business Wire